1H-苯并咪唑-2,5-二胺(9ci) | 85561-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1H-苯并咪唑-2,5-二胺(9ci)
• 中文别名: 1-氢-苯并咪唑-2,5-二胺
• 英文名称: 1H-benzo[d]imidazole-2,5-diamine
• 英文别名: 3H-benzimidazole-2,5-diamine
• CAS: 85561-97-3
• 化学式: C₇H₈N₄
• 分子量: 148.167
• InChiKey: IFNLHIRHJNDMBM-UHFFFAOYSA-N

物化性质

• 沸点：
  476.6±37.0 °C(Predicted)
• 密度：
  1.486±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.7
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1H-苯并咪唑-2,5-二胺(9ci) 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2,5-diaminobenzimidazole dihydrochloride salt
  参考文献：
  名称：

  2-氨基苯并咪唑衍生物强烈抑制和分散铜绿假单胞菌生物膜

  摘要：

  使用传统抗生素很难清除细菌生物膜，对健康构成重大威胁。2-氨基苯并咪唑衍生物（见方案）能够强烈抑制铜绿假单胞菌生物膜的生长和分散。发现这些分子可调节报告菌株中的群体感应，并代表一些已知的最强铜绿假单胞菌生物膜抑制剂。

  DOI：

  10.1002/anie.201109258
• 作为产物：
  描述：

  2-氯苯并咪唑 在 palladium on activated charcoal 硫酸 、 氨 、 氢气 、 硝酸 作用下， 以 乙醇 为溶剂， 生成 1H-苯并咪唑-2,5-二胺(9ci)
  参考文献：
  名称：

  Novel benzimidazole-based MCH R1 antagonists

  摘要：

  The identification of an MCH R1 antagonist screening hit led to the optimization of a class of benzimidazole-based MCH R1 antagonists. Structure-activity relationships and efforts to optimize pharmacokinetic properties are detailed along with the demonstration of the effectiveness of an MCH R1 antagonist in an animal model of obesity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.054

文献信息

• [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098421A1

  公开（公告）日：2017-06-15

  The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代苯并噻二嗪衍生物。具体而言，本发明涉及式(I)化合物：其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病，如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
• [EN] 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE 5-SULFAMOYL-2-HYDROXYBENZAMIDE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017153952A1

  公开（公告）日：2017-09-14

  The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代水杨酰胺衍生物。具体而言，本发明涉及根据公式(I)的化合物：其中R、R1和R2如本文所述，或其药用可接受的盐。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌症综合症以及与CD73抑制相关的疾病，例如艾滋病、治疗HIV、自身免疫疾病、感染、动脉粥样硬化和缺血再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制CD73活性和治疗与之相关的疾病的方法。
• [EN] DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS<br/>[FR] DIAMINO-PYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE L'ANGIOGENESE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003074515A1

  公开（公告）日：2003-09-12

  Benzimidazole derivatives of formula (I) , which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. (I)

  本发明描述了公式(I)的苯并咪唑衍生物，它们作为TIE-2和/或VEGFR-2抑制剂是有用的。所描述的发明还包括制造这样的苯并咪唑衍生物的方法，以及使用它们在治疗增生性疾病中的方法。
• Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives
  申请人：BLACKWELL Helen

  公开号：US20130136782A1

  公开（公告）日：2013-05-30

  Compounds described herein inhibit biofilm formation or disperse pre-formed biofilms of Gram-negative bacteria. Biofilm-inhibitory compounds can be encapsulated or contained in a polymer matrix for controlled release. Coatings, films, multilayer films, hydrogels, microspheres and nanospheres as well as pharmaceutical compositions and disinfecting compositions containing biofilm-inhibitory compounds are also provided. Methods for inhibiting formation of biofilms or dispersing already formed biofilms are provided. Methods for treating infections of gram-negative bacteria which form biofilms, particularly those of Pseudomonas and more particularly P. aeruginosa.

  本文描述的化合物可以抑制革兰氏阴性细菌的生物膜形成或分散已形成的生物膜。生物膜抑制化合物可以被封装或包含在聚合物基质中以进行控制释放。此外，还提供了包含生物膜抑制化合物的涂层、薄膜、多层薄膜、水凝胶、微球和纳米球，以及含有生物膜抑制化合物的制药组合物和消毒组合物。提供了抑制生物膜形成或分散已形成生物膜的方法。还提供了治疗革兰氏阴性细菌感染的方法，特别是那些形成生物膜的假单胞菌，尤其是P. aeruginosa。
• [EN] SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS ß-SECRETASE INHIBITORS<br/>[FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES, ET PROCÉDÉS D'UTILISATION COMME INHIBITEURS DE LA ?-SÉCRÉTASE
  申请人：HIGH POINT PHARMACEUTICALS LLC

  公开号：WO2010126745A1

  公开（公告）日：2010-11-04

  The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.

  本发明涉及替代咪唑[1,2-a]吡啶衍生物，其药学上可接受的盐，以及这些化合物或盐的互变异构体，其抑制β-淀粉样前体蛋白裂解酶（BACE）并且可能在治疗涉及BACE的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物以及在治疗涉及BACE的这类疾病中使用这些化合物和组合物。